Risk factors for non-responsiveness to 5-aminosalicylic acid in patients with ulcerative colitis identified using retrospective clinical study and Mendelian randomization

被引:0
|
作者
Ye, Zhi-Ning [1 ,2 ]
Liu, Xin-Tian [1 ,2 ]
Gu, Yue-Ming [1 ,2 ]
Mao, Shu-Xian [3 ,4 ]
Liang, Dan-Hong [1 ,2 ]
Zhan, Kai [1 ,2 ]
Lei, Hao-Qiang [5 ]
Huang, Shao-Gang [3 ,4 ]
机构
[1] Guangzhou Univ Chinese Med, Affiliated Dongguan Hosp, Dongguan, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Coll 9, Dongguan, Peoples R China
[3] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Gastroenterol, 16 Airport Rd, Guangzhou 510120, Peoples R China
[4] Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China
[5] Huangpu Peoples Hosp Zhongshan, Zhongshan, Peoples R China
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
基金
中国国家自然科学基金;
关键词
Ulcerative colitis; 5-Aminosalicylic acid; Responsiveness; Allergy; Aspartate aminotransferase-to-alanine aminotransferase ratio; Inhibitor of nuclear factor kappa-B kinase subunit alpha; INFLAMMATORY-BOWEL-DISEASE; MESALAZINE; POLYMORPHISMS; ASSOCIATION;
D O I
10.1038/s41598-025-89620-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This study aimed to identify risk factors and potential targets associated with non-responsiveness to 5-Aminosalicylic acid (5-ASA) in patients with ulcerative colitis (UC). Patients with mild to moderate UC were grouped based on their responsiveness to 5-ASA. Regression analysis was conducted to identify risk factors for non-responsiveness, while Mendelian randomization (MR) analysis was used to evaluate the potential targets. Among 50 patients (11 non-responders and 39 responders), non-responders exhibited higher incidences of fever, back pain, allergy history, and ankylosing spondylitis, as well as elevated monocyte count and alanine aminotransferase (ALT) level, but a lower aspartate aminotransferase-to-ALT (AST/ALT) ratio (all P < 0.05). Allergy history was a risk factor (OR 140.50, P = 0.021), while a high AST/ALT ratio was a protective factor (OR 0.001, P = 0.023) for non-responsiveness. The area under the receiver operating characteristic curve for the AST/ALT ratio was 0.80. MR analysis showed that inhibition of the inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) by 5-ASA, targeting ALT, increased the risk of UC (OR 1.02, P = 0.002). Our findings suggested that allergy history and the AST/ALT ratio were associated with non-responsiveness to 5-ASA, and CHUK was identified as a potential target for ALT-related non-responsiveness.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine
    Karamanolis, DG
    Papatheodoridis, GV
    Xourgias, V
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (11) : 1083 - 1088
  • [12] Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance
    Matsumoto, Hiroshi
    Sasahira, Momoyo
    Go, Tei Tei
    Yo, Shogen
    Ninomiya, Takehiro
    Osawa, Motoyasu
    Handa, Osamu
    Umegami, Eiji
    Inoue, Ryo
    Shiotani, Akiko
    BIOMEDICINES, 2024, 12 (09)
  • [13] Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment
    Elkjaer, Margarita
    Burisch, Johan
    Avnstrom, Soren
    Lynge, Elsebeth
    Munkholm, Pia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (06) : 695 - 704
  • [14] Development and validation of a nomogram to predict non-response to 5-aminosalicylic acid in patients with ulcerative colitis
    Dai, Cong
    Dong, Zi-Yuan
    Wang, Yi-Nuo
    Huang, Yu -Hong
    Jiang, Min
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (03) : 124 - 131
  • [15] The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry
    Fukuda, Tomohiro
    Naganuma, Makoto
    Sugimoto, Shinya
    Nanki, Kosaku
    Mizuno, Shinta
    Mutaguchi, Makoto
    Nakazato, Yoshihiro
    Inoue, Nagamu
    Ogata, Haruhiko
    Iwao, Yasushi
    Kanal, Takanori
    PLOS ONE, 2017, 12 (11):
  • [16] Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Moshkovska, Tetyana
    Stone, Margaret
    Baker, Richard
    Mayberry, John
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (06) : 763 - 768
  • [17] Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study
    Prosberg, Michelle V.
    Vester-Andersen, Marianne K.
    Andersson, Mikael
    Jess, Tine
    Andersen, Jon T.
    Vind, Ida
    Bendtsen, Flemming
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) : 925 - 932
  • [18] PREVENTION OF RELAPSE IN ULCERATIVE-COLITIS USING ORAL OR TOPICAL 5-AMINOSALICYLIC ACID THERAPY
    SUTHERLAND, LR
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1993, 7 (02): : 232 - 236
  • [19] Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase
    Madarame, Akira
    Fukuzawa, Masakatsu
    Yamauchi, Yoshiya
    Kono, Shin
    Sugimoto, Akihiko
    Yamaguchi, Hayato
    Morise, Takashi
    Koyama, Yohei
    Uchida, Kumiko
    Suguro, Maya
    Matsumoto, Taisuke
    Yasuyuki, Kagawa
    Kawai, Takashi
    Itoi, Takao
    PLOS ONE, 2021, 16 (08):
  • [20] Medication Use Patterns and Predictors of Nonpersistence and Nonadherence with Oral 5-Aminosalicylic Acid Therapy in Patients with Ulcerative Colitis
    Yen, Linnette
    Wu, Joanne
    Hodgkins, Paul
    Cohen, Russell D.
    Nichol, Michael B.
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (09): : 701 - 712